Toggle light / dark theme

Kelsey Moody at Ending Age-Related Diseases 2019

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Dr. Kelsey Moody gave a detailed presentation on macular degeneration, discussing its origins in the lysosomes and how it progresses along with how his company, Ichor Therapeutics, is developing an exogenous enzyme treatment that may cure this crippling disease.

Reason at Ending Age-Related Diseases 2019

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

In his talk, Reason of Repair Biotechnologies addressed the reasons why rejuvenation biotechnology is not proceeding as fast as it could be and discussed the ways in which his company is helping to expedite its development and release.

Cyborgs and immortality: into the research of Dr. Huberman

Who doesn’t want to live forever?

Every society has its own set of myths about finding eternal life: the Fountain of Youth for the Spaniards and Shangri La for the Chinese, for example. For the transhumanists, this myth may become a reality.

Dr. Jennifer Huberman is a cultural anthropology professor at UMKC whose recent research has focused on this emerging high-tech society. Initially, Huberman did not set out to study the transhumanists.

Greg Fahy at Ending Age-Related Diseases 2019

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Dr. Greg Fahy of Intervene Immune gave a presentation about his company’s Phase 1 human trials in which the thymus, a critical organ of the immune system, was regenerated through a combination of existing drugs, restoring immune function and causing epigenetic biomarkers to show rejuvenation.

AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine

A unified theory of ageing, there is a vid and a paper linked within.


ALAMEDA, Calif.—( )—AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology. The paper presents the work of the company’s scientists in describing a unified theory of aging and regeneration that could pave the way for the development of new therapies for a variety of age-related degenerative diseases and conditions.

“The longevity sector is advancing at an accelerating pace, but for the most part, without a consensus on the fundamental root causes of aging,” commented Dr. West. “We believe that it is now possible to collate the diverse observations about aging into a unified model. In the paper titled, ‘Toward a Unified Theory of Aging and Regeneration’ we outline such a theory that underlies the technological underpinnings of the company’s induced tissue regeneration (iTR) program.”

/* */